51.99 USD
+0.03 (+0.06%)
51.99 USD
0 (0%)
Overall CCXI gets a fundamental rating of 3 out of 10. We evaluated CCXI against 525 industry peers in the Biotechnology industry. CCXI has a bad profitability rating. Also its financial health evaluation is rather negative. CCXI is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
- In the past year CCXI has reported negative net income.
- CCXI had a negative operating cash flow in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.74% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -353.17% | ||
| PM (TTM) | -357.01% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- CCXI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, CCXI has more shares outstanding
- The debt/assets ratio for CCXI is higher compared to a year ago.
2.2 Solvency
- An Altman-Z score of 9.70 indicates that CCXI is not in any danger for bankruptcy at the moment.
- CCXI has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.7 |
ROIC/WACCN/A
WACC9.62%
2.3 Liquidity
- A Current Ratio of 4.54 indicates that CCXI has no problem at all paying its short term obligations.
- CCXI has a Quick Ratio of 4.47. This indicates that CCXI is financially healthy and has no problem in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.54 | ||
| Quick Ratio | 4.47 |
3. Growth
3.1 Past
- The earnings per share for CCXI have decreased by -6.78% in the last year.
- Looking at the last year, CCXI shows a very strong growth in Revenue. The Revenue has grown by 72.49%.
- Measured over the past years, CCXI shows a very strong growth in Revenue. The Revenue has been growing by 21.96% on average per year.
EPS 1Y (TTM)-6.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.43%
Revenue 1Y (TTM)72.49%
Revenue growth 3Y-9.08%
Revenue growth 5Y21.96%
Sales Q2Q%548.81%
3.2 Future
- CCXI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.34% yearly.
- Based on estimates for the next years, CCXI will show a very strong growth in Revenue. The Revenue will grow by 134.59% on average per year.
EPS Next Y9.69%
EPS Next 2Y37.13%
EPS Next 3Y41.06%
EPS Next 5Y47.34%
Revenue Next Year117.77%
Revenue Next 2Y157.52%
Revenue Next 3Y130.02%
Revenue Next 5Y134.59%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- CCXI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year CCXI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -26.68 |
4.3 Compensation for Growth
- CCXI's earnings are expected to grow with 41.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.13%
EPS Next 3Y41.06%
5. Dividend
5.1 Amount
- No dividends for CCXI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
51.99
+0.03 (+0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2022-08-08/amc
Earnings (Next)11-08 2022-11-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners0.37%
Ins Owner Change0%
Market Cap3.71B
Revenue(TTM)37.28M
Net Income(TTM)-133.09M
Analysts52.31
Price Target53.04 (2.02%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.65%
Min EPS beat(2)-73.94%
Max EPS beat(2)12.63%
EPS beat(4)3
Avg EPS beat(4)-7.25%
Min EPS beat(4)-73.94%
Max EPS beat(4)29.7%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-41.92%
Min Revenue beat(2)-74.96%
Max Revenue beat(2)-8.87%
Revenue beat(4)1
Avg Revenue beat(4)-25.25%
Min Revenue beat(4)-74.96%
Max Revenue beat(4)29.07%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 99.51 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 15.68 | ||
| P/tB | 15.68 | ||
| EV/EBITDA | -26.68 |
EPS(TTM)-1.89
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0.52
BVpS3.31
TBVpS3.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.74% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -353.17% | ||
| PM (TTM) | -357.01% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 134.75% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.54 | ||
| Quick Ratio | 4.47 | ||
| Altman-Z | 9.7 |
F-Score3
WACC9.62%
ROIC/WACCN/A
Cap/Depr(3y)860.12%
Cap/Depr(5y)583.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.43%
EPS Next Y9.69%
EPS Next 2Y37.13%
EPS Next 3Y41.06%
EPS Next 5Y47.34%
Revenue 1Y (TTM)72.49%
Revenue growth 3Y-9.08%
Revenue growth 5Y21.96%
Sales Q2Q%548.81%
Revenue Next Year117.77%
Revenue Next 2Y157.52%
Revenue Next 3Y130.02%
Revenue Next 5Y134.59%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.33%
OCF growth 3YN/A
OCF growth 5YN/A
CHEMOCENTRYX INC / CCXI FAQ
What is the ChartMill fundamental rating of CHEMOCENTRYX INC (CCXI) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CCXI.
What is the valuation status of CHEMOCENTRYX INC (CCXI) stock?
ChartMill assigns a valuation rating of 0 / 10 to CHEMOCENTRYX INC (CCXI). This can be considered as Overvalued.
How profitable is CHEMOCENTRYX INC (CCXI) stock?
CHEMOCENTRYX INC (CCXI) has a profitability rating of 3 / 10.
Can you provide the financial health for CCXI stock?
The financial health rating of CHEMOCENTRYX INC (CCXI) is 6 / 10.